Business Daily Media

Men's Weekly

.

LTS wins funding from BARDA’s Patch Forward Prize Competition for two partnerships

ANDERNACH, GERMANY - Newsaktuell - 14 January 2025 - LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company, is proud to announces its selection as a Concept Stage winner for two projects in the #PatchForwardPrize, a $50 million challenge by the Biomedical Advanced Research and Development Authority (BARDA) to advance microneedle patch-based RNA vaccine technologies.



LTS
LTS' proprietary dissolvable microneedle array patch technology with mRNA vaccines aims for the development of next generation vaccine technologies. Source: LTS LOHMANN Therapie-Systeme AG

The Patch Forward Prize, part of the Project NextGen initiative led by BARDA, aims to accelerate next-generation vaccine technologies. By fostering partnerships between vaccine developers and delivery platform innovators, the competition drives progress from concept to clinical stages, paving the way for transformative advancements in global health. Each of the prizes announced today represents an award of US$ 2 million, that will be shared between LTS and its partners.

The awarded projects bring together LTS's proprietary dissolvable Microneedle Array Patch (MAP) technology with mRNA vaccines from two partners, BioNet, a biotech manufacturer specializing in genetically engineered vaccines and PopVax, an Indian full-stack biotechnology company developing broadly-protective mRNA vaccines using machine learning-enabled computational protein design.

Both projects aim to address critical challenges in vaccine stability, delivery, and adaptability, with the potential to improve patient access and compliance. The focus will be on seasonal influenza vaccines, with the ability to pivot to pandemic strains if necessary.

BioNet's approach tackles the ongoing challenge of influenza strain variability by developing a trivalent seasonal influenza mRNA vaccine (mIV3) that targets conserved regions of the hemagglutinin (HA) and neuraminidase (NA) proteins from dominant H1N1, H3N2, and B influenza viruses. These mRNA constructs are carefully selected to elicit broad protective immune responses against seasonal influenza.

PopVax is leading the effort to develop a seasonal influenza vaccine built on their novel mRNA-encoded immunogen display architecture and LNP platform. PopVax's immunogen design and display approach boosts the elicited strain-specific antibody response by as much as 250x in mice in comparison with a leading approved influenza vaccine, leading to significantly lower dosage requirements. This approach also elicits a broader immune response, including robust antibody titer against pandemic H5N1 influenza, a rising threat in the United States, despite not encoding an H5N1-specific immunogen.

LTS CEO Bas van Buijtenen commented: "As a front-runner in drug delivery, we care passionately about solutions that provide better outcomes and better patient experience. We are grateful and proud that Barda's Patch Forward prize provides an opportunity to BioNet, PopVax and LTS to create a breakthrough in vaccine administration. We look forward to delivering on the promise of the combination of our technologies through our joint programs."

"LTS Microneedle-Array-Patch (Map)-Program is proud to have received those 2 awards together with our partners PopVax and BioNet, with their innovative mRNA technologies", added Dr. Frank Theobald, Head of MAP Program at LTS. "The BARDA Patch Forward Price allows combination of 2 breakthrough technologies to be better prepared for the next pandemics to come. The financial support from BARDA will help to advance the MAP technology towards commercialization addressing an unmet medical need and offering the opportunity for self-administration as well as the opportunity for lowering the cold-chain requirements for mRNA."

- Picture is available at AP -


Hashtag: #FEV

The issuer is solely responsible for the content of this announcement.

About LTS

We CARE. We CREATE. We DELIVER. The driving philosophy behind LTS. As a trusted technology partner for the pharmaceutical industry, we develop and manufacture innovative drug delivery systems such as Transdermal Patches ("TTS") and Oral Thin Films ("OTF") as well as wearable drug delivery devices ("OBDS"). LTS´ commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 40 development projects targeting multiple disease indications. LTS's innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Microneedle Array Patches ("MAP") for the transdermal delivery of small and large molecules, biological actives and vaccines. With its SorrelTM wearable drug delivery platform LTS offers patient friendly solutions for complex drugs delivery at home. Founded in 1984, LTS operates today from four sites: in Andernach, Germany, West Caldwell, NJ, USA, St. Paul, MN, USA and Netanya, Israel. LTS has also a representative office in Shanghai, China.

News from Asia

Hong Kong Men Prioritise Tech Over Health, New Study Reveals

AXA Global Healthcare study highlights worrying gaps in how men prioritise their mental and physical health HONG KONG SAR - Media OutReach Newswire - 22 July 2025 - Men in Hong Kong are signi...

Swiss-Belhotel Brisbane Marks Six-Month Milestone

Strategically located next to The Gabba, the 110-room property affirms Swiss-Belhotel International’s growing footprint in AustraliaBRISBANE, AUSTRALIA - Media OutReach Newswire - 22 July 2025 - S...

AUPU’s ARCHIDEX 2025 Triumph: Redefining Home Comfort in SE Asia

KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 22 July 2025 - ARCHIDEX 2025 wasn't just an exhibition—it was a statement. AUPU, a global leader in home comfort tech, solidified its position as...

Singapore’s most beloved local F&B brands revealed: foodpanda unveils first-ever Local Foodie Heroes Hall of Fame

A delicious tribute to Singapore’s iconic local eats to mark SG60 celebrations – enjoy close to two months of exclusive launch deals SINGAPORE - Media OutReach Newswire - 22 July 2025 - Get ready ...

Encountering Naadam, Experiencing the 35th Grassland Carnival of the Inner Mongolia Autonomous Region

XILINGOL LEAGUE, CHINA - Media OutReach Newswire - 22 July 2025 - Mid-summer breathes life into Inner Mongolia's grassland, where lush pastures glisten after seasonal rains, nourishing herds benea...

Putting People First: ONYX Hospitality Group's Strategy for Sustainable Leadership

By nurturing talent and cultivating a high-impact culture, ONYX redefines hospitality excellence.BANGKOK, THAILAND - Media OutReach Newswire - 22 July 2025 - ONYX Hospitality Group, a leading hosp...

Wel-Bloom Biotech Launches Wel-ROS6. Black Crystal Roselle Sparks a Surge in High-Concentration Anthocyanins

Black Crystal Roselle Anthocyanin Levels Surge 17.7x — Wel-Bloom Biotech Elevates Taiwan’s Global Ingredient Competitiveness Black Crystal Roselle Shakes Up the Anthocyanin Market...

Lee Kuan Yew School of Public Policy Releases Strategic Roadmap for ASEAN's 5G-AI Transformation

New Research Reveals US$130 Billion Economic Opportunity and Outlines Policy Framework to Accelerate Regional Digital Leadership by 2030SINGAPORE - Media OutReach Newswire - 22 July 2025 - The Le...

DFI Retail Group Holdings Limited Half-Year Results For The Six Months Ended 30 June 2025 And Announcement Of Special Dividend

Highlights 39% underlying earnings growth Increased contributions from associates, Health & Beauty and Food Health & Beauty delivered strong like-for-like (LFL...

HeyMax Acquires Hong Kong’s krip to Accelerate Regional Expansion into Loyalty and Rewards Market

HeyMax’s first acquisition fast-tracks its regional expansion, bringing over 6,000 credit card deals offered by over 3,000 merchants, and personalized loyalty experiences to consumers in Hong Kong ...

Baby boomers are driving development feasibility leading to larger apartments

As residential developers continue to grapple with feasibility issues on apartment projects, the sector is struggling to deliver volumes of new st...

Hays launches FY25/26 Salary Guide: ‘Salary Paradox’ deepens as pay rises fail Australians

Rising dissatisfaction with pay, progression and perks is fuelling a new wave of career change in FY25/26, as Australians demand more from employe...

Australian Businesses Still Stuck in the AI Hype Cycle

Data Governance Failures, ROI Gaps and Unclear Strategy Slowing Progress Despite artificial intelligence (AI) dominating headlines and boardroom ag...

How to ensure your manufacturing business survives international tariff turmoil

Optimising your operations in FY2026 will help you combat the challenges of a volatile trading environment. Up, down, in out…Since the commence...

Why Apptio is Enhancing Visibility into AI and Hybrid Cloud

AI investments have become a strategic priority for business with the mindset that if you're not using AI, you're falling behind. But according to...

Beyond borders: Building a scalable strategy for international hiring

For many Australian businesses, growth increasingly depends on thinking beyond local borders.  As wage pressures rise, and specialised talent pool...

Sell by LayBy